You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameUstekinumabProduct NameSTELARA®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassImmunosuppressantsPharmacological SubgroupImmunosuppressantsChemical SubgroupInterleukin InhibitorsCondition StudiedPsoriasis
Sponsor Protocol NumberCNTO1275PSA3002 /// PSUMMIT IIEnrollment312Data PartnerJohnson & Johnson% Female52.6%Mean/Median Age (Years)49% White98.4%
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0436 : EXploring SEx-related Mechanisms of Psoriatic Arthritis response to advanced therapies (EXSEMP): Individual participant data (IPD) meta-analysis
- 2023-5145 : Improving efficiency of immune-mediated inflammatory disease trials through better design and analysis
- 2019-4067 : Evidence-generation for biologics in pediatric studies
- 2017-1746 : Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity
- 2017-1456 : The efficacy of biologic medications in improving depressive symptoms in patients with PsA ? Patient-level meta-analysis
- 2016-0897 : A systematic review and economic evaluation of certolizumab pegol and secukinumab for treating active psoriatic arthritis
- 2015-0560 : Construct and Content Validity of Instruments Used in Clinical Trials of Psoriatic Arthritis
- 2015-0339 : Impact of the dose of immunomodulators on pharmacokinetics of biologics: Patient level meta-analysis of randomized controlled trials